Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: A comparison of weekly vs triweekly regimens

Targeted Oncology

Volumn 1, Issue 2, 2006, Pages 86-89

  Saito, Keiko ^a   Kikuchi, Yoshihiro ^b   Fujii, Kazuyuki ^c   Kita, Tsunekazu ^c   Furuya, Kenichi ^c  

^a National Hospital Organization   (Japan)

^b Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Angiogenesis; IL 8; Ovarian cancer; VEGF; Weekly paclitaxel

Indexed keywords

EID: 33746044139     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-006-0012-7     Document Type: Article

References (20)

1. Colombo N, Parma G, Bocciolone L, Sider M, Franchi D, Maggioni A (1999) Role of chemotherapy in relapsed ovarian cancer. Crit Rev Oncol Hematol 32:221-228
2. Kita T, Kikuchi Y, Takano M, Suzuki M, Oowada M, Konnno R, Yamamoto K, Inoue H, Seto H, Yamamoto T, Shimizu K (2004) The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 92:813-818
3. Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195-1206
4. Kerbel RS, Klement G, Pritchard KI, Kamen B (2002) Continuous low-dose antiangiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13:5
5. Dehanen K, Taylor DD, Gercel-Taylor C (2002) Comparison of serum vascular endothelial growth factor levels between patients with and without ovarian malignancies. Int J Gynecol Cancer 12:715-719
6. Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG (1997) Up-regulation of interleukin-8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 186:1201-1212
7. Koch AE, Polverini PJ, Kunkel SL et al (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801
8. Browder T, Butterflied CE, Kraaling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886
9. Lau D, Guo L, Gandara D, Young LJT, Xue L (2004) Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs 15:871-875
10. Olson T, Mohanraj D, Carson L, Ramakrisnan S (1994) Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276-280
11. Folkman J (1995) Clinical applications of research on angiogenesis. New Engl J Med 333:1757-1763
12. Abulafia O, Sherer DM (2000) Angiogenesis of the ovary. Am J Obstet Gynecol 182:240-246
13. Paley PJ, Staskus KA, Gebhard K et al (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98-106
14. Yamamoto S, Konishi I, Mandai M et al (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms; correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221-1227
15. Kim SJ, Choi IK, Park KH et al (2004) Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol 34:184-190
16. Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992
17. Koumakis G, Demiri M, Barbounis V et al (2002) Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial. Lung Cancer 35:315-317
18. Ukena D, Schroeder M, Dittrich I et al (2003) Phase III randomized trial comparing paclitaxel/carboplatin every 3 weeks witli weekly paclitaxel/ carboplatin in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 22:623 (Abstr)
19. Balavi CP, Barstis J, Perry MC et al (2003) Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21:2933-2939
20. Goble S, Bear HD (2003) Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am 83:943-971